Johnson & Johnson

JnJ have revealed new data on its new depression drug esketamine, its chemically ‘left-handed’ version of the controlled anaesthetic often used recreationally, creating a varied viewed of its efficacy. JnJ’s drug, which is delivered by a nasal spray, was tested in treatment-resistant depression, defined as unaffected by two or more currently available antidepressant medications of

J&J and its scientific collaborators are investigating whether changing the formulation of the vaccine antigens during the regimen – a ‘heterologous prime boost’ – can improve immune responses. After encouraging results in non-human primates for HIV vaccines, Johnson & Johnson (J&J) have now started enrolling volunteers.

Genmab and their partner Johnson & Johnson have today announced positive mid-stage clinical data on daratumumab for multiple myeloma. The preliminary results are from a 124-patient Phase II client trial of daratumumab in double refractory multiple myeloma conducted by J&J’s Janssen Biotech unit. The results show an overall response rate of 29.2% in the 16

Johnson & Johnson and Vectura have announced a new partnership to develop anti-inflammatory therapies for asthma and chronic obstructive pulmonary disease (COPD). Vectura, who are respiratory specialists, confirmed that the collaboration will primarily focus on a Phase II treatment, but may also include additional clinical-stage candidates.

Johnson & Johnson (J&J) has announced that they have received regulatory approvals on both sides of the Atlantic for Olysio and Invokana. The US regulatory body, the Food and Drug Administration (FDA), approved Olysio (simeprevir) on Friday to treat chronic hepatitis C virus infection. The drug was co-developed with Sweden’s Medivir.

GlaxoSmithKline and Johnson & Johnson (J&J) announced yesterday that they have started Phase III clinical trials of their investigational rheumatoid arthritis (RA) treatment, sirukumab. Johnson & Johnson’s Janssen Biologics unit in Ireland and GlaxoSmithKline have begun a Phase III development programme for sirukumab (otherwise known as CNTO 136), a human anti-interleukin (IL)-6 monoclonal antibody. The

Johnson & Johnson’s Janssen Research & Development unit yesterday announced that they have filed a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for bedaquiline, in the hope that it will be the first drug with a new mechanism of action for tuberculosis (TB) in over 40 years. Specifically, Janssen is

Janssen Research & Development announced earlier this week that they have submitted supplemental New Drug Applications (sNDAs) to the US FDA (Food and Drug Administration). Janssen are pursuing approval from the FDA for the use of XARELTO (rivaroxaban), an oral anticoagulant, to treat patients with deep vein thrombosis (DVT) or pulmonary embolism (PE) and prevention

It has been reported that Johnson & Johnson’s bid to resolve alleged claims of illegal marketing of the antipsychotic blockbuster, Risperdal, which could cost the organisation about $1 billion, has been scuppered by the US Department of Justice. A tentative deal between Johnson & Johnson and federal prosecutors in Philadelphia was reached a couple of